Yaoting Sun, He Wang, Lu Li, Jianbiao Wang, Wanyuan Chen, Li Peng, Pingping Hu, Jing Yu, Xue Cai, Nan Yao, Yan Zhou, Jiatong Wang, Yingrui Wang, Liqin Qian, Weigang Ge, Mengni Chen, Feng Yang, Zhiqiang Gui, Wei Sun, Zhihong Wang, Minghua Ge, Yi He, Guangzhi Wang, Yongfu Zhao, Huanjie Chen, Xiaohong Wu, Yuxin Du, Wenjun Wei, Fan Wu, Dingcun Luo, Xiangfeng Lin, Haitao Zheng, Xin Zhu, Bei Wei, Jiafei Shen, Jincao Yao, Zhennan Yuan, Tong Liu, Jun Pan, Yifeng Zhang, Yangfan Lv, Qiaonan Guo, Qijun Wu, Tingting Gong, Ting Chen, Shu Zheng, Jingqiang Zhu, Hanqing Liu, Chuang Chen, Hong Han, Sathiyamoorthy Selvarajan, Michael Mingzhao Xing, Kennichi Kakudo, Erik K Alexander, Yijun Wu, Yu Wang, Dong Xu, Hao Zhang, Xiu Nie, Oi Lian Kon, N Gopalakrishna Iyer, Zhiyan Liu, Yi Zhu, Haixia Guan, Tiannan Guo
{"title":"基于蛋白的甲状腺滤泡腺瘤和癌鉴别分类器。","authors":"Yaoting Sun, He Wang, Lu Li, Jianbiao Wang, Wanyuan Chen, Li Peng, Pingping Hu, Jing Yu, Xue Cai, Nan Yao, Yan Zhou, Jiatong Wang, Yingrui Wang, Liqin Qian, Weigang Ge, Mengni Chen, Feng Yang, Zhiqiang Gui, Wei Sun, Zhihong Wang, Minghua Ge, Yi He, Guangzhi Wang, Yongfu Zhao, Huanjie Chen, Xiaohong Wu, Yuxin Du, Wenjun Wei, Fan Wu, Dingcun Luo, Xiangfeng Lin, Haitao Zheng, Xin Zhu, Bei Wei, Jiafei Shen, Jincao Yao, Zhennan Yuan, Tong Liu, Jun Pan, Yifeng Zhang, Yangfan Lv, Qiaonan Guo, Qijun Wu, Tingting Gong, Ting Chen, Shu Zheng, Jingqiang Zhu, Hanqing Liu, Chuang Chen, Hong Han, Sathiyamoorthy Selvarajan, Michael Mingzhao Xing, Kennichi Kakudo, Erik K Alexander, Yijun Wu, Yu Wang, Dong Xu, Hao Zhang, Xiu Nie, Oi Lian Kon, N Gopalakrishna Iyer, Zhiyan Liu, Yi Zhu, Haixia Guan, Tiannan Guo","doi":"10.1038/s44321-025-00242-2","DOIUrl":null,"url":null,"abstract":"<p><p>Differentiating follicular thyroid adenoma (FTA) from carcinoma (FTC) remains challenging due to similar histological features separate from invasion. This study developed and validated DNA- and/or protein-based classifiers. A total of 2443 thyroid samples from 1568 patients were obtained from 24 centers in China and Singapore. Next-generation sequencing of a 66-gene panel revealed 41 (62.1%) detectable genes, while 25 were not, showing similar alteration patterns with differing mutation frequencies. Proteomics quantified 10,336 proteins, with 187 dysregulated. A discovery protein-based XGBoost model achieved an AUROC of 0.899 (95% CI, 0.849-0.949), outperforming the gene-based model (AUROC 0.670 [95% CI, 0.612-0.729]). A subsequent 24-protein classifier, developed via targeted mass spectrometry and validated in three independent sets, showed high performance in retrospective cohorts (AUROC 0.871 [95% CI, 0.833-0.910] and 0.853 [95% CI, 0.772-0.934]) and prospective biopsies (AUROC 0.781 [95% CI, 0.563-1.000]). It exhibited a 95.7% negative predictive value for ruling out malignancy. This study presents a promising protein-based approach for the differential diagnosis of FTA and FTC, potentially enhancing diagnostic accuracy and clinical decision-making.</p>","PeriodicalId":11597,"journal":{"name":"EMBO Molecular Medicine","volume":" ","pages":""},"PeriodicalIF":9.0000,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A protein-based classifier for differentiating follicular thyroid adenoma and carcinoma.\",\"authors\":\"Yaoting Sun, He Wang, Lu Li, Jianbiao Wang, Wanyuan Chen, Li Peng, Pingping Hu, Jing Yu, Xue Cai, Nan Yao, Yan Zhou, Jiatong Wang, Yingrui Wang, Liqin Qian, Weigang Ge, Mengni Chen, Feng Yang, Zhiqiang Gui, Wei Sun, Zhihong Wang, Minghua Ge, Yi He, Guangzhi Wang, Yongfu Zhao, Huanjie Chen, Xiaohong Wu, Yuxin Du, Wenjun Wei, Fan Wu, Dingcun Luo, Xiangfeng Lin, Haitao Zheng, Xin Zhu, Bei Wei, Jiafei Shen, Jincao Yao, Zhennan Yuan, Tong Liu, Jun Pan, Yifeng Zhang, Yangfan Lv, Qiaonan Guo, Qijun Wu, Tingting Gong, Ting Chen, Shu Zheng, Jingqiang Zhu, Hanqing Liu, Chuang Chen, Hong Han, Sathiyamoorthy Selvarajan, Michael Mingzhao Xing, Kennichi Kakudo, Erik K Alexander, Yijun Wu, Yu Wang, Dong Xu, Hao Zhang, Xiu Nie, Oi Lian Kon, N Gopalakrishna Iyer, Zhiyan Liu, Yi Zhu, Haixia Guan, Tiannan Guo\",\"doi\":\"10.1038/s44321-025-00242-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Differentiating follicular thyroid adenoma (FTA) from carcinoma (FTC) remains challenging due to similar histological features separate from invasion. This study developed and validated DNA- and/or protein-based classifiers. A total of 2443 thyroid samples from 1568 patients were obtained from 24 centers in China and Singapore. Next-generation sequencing of a 66-gene panel revealed 41 (62.1%) detectable genes, while 25 were not, showing similar alteration patterns with differing mutation frequencies. Proteomics quantified 10,336 proteins, with 187 dysregulated. A discovery protein-based XGBoost model achieved an AUROC of 0.899 (95% CI, 0.849-0.949), outperforming the gene-based model (AUROC 0.670 [95% CI, 0.612-0.729]). A subsequent 24-protein classifier, developed via targeted mass spectrometry and validated in three independent sets, showed high performance in retrospective cohorts (AUROC 0.871 [95% CI, 0.833-0.910] and 0.853 [95% CI, 0.772-0.934]) and prospective biopsies (AUROC 0.781 [95% CI, 0.563-1.000]). It exhibited a 95.7% negative predictive value for ruling out malignancy. This study presents a promising protein-based approach for the differential diagnosis of FTA and FTC, potentially enhancing diagnostic accuracy and clinical decision-making.</p>\",\"PeriodicalId\":11597,\"journal\":{\"name\":\"EMBO Molecular Medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":9.0000,\"publicationDate\":\"2025-05-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EMBO Molecular Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s44321-025-00242-2\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EMBO Molecular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s44321-025-00242-2","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
A protein-based classifier for differentiating follicular thyroid adenoma and carcinoma.
Differentiating follicular thyroid adenoma (FTA) from carcinoma (FTC) remains challenging due to similar histological features separate from invasion. This study developed and validated DNA- and/or protein-based classifiers. A total of 2443 thyroid samples from 1568 patients were obtained from 24 centers in China and Singapore. Next-generation sequencing of a 66-gene panel revealed 41 (62.1%) detectable genes, while 25 were not, showing similar alteration patterns with differing mutation frequencies. Proteomics quantified 10,336 proteins, with 187 dysregulated. A discovery protein-based XGBoost model achieved an AUROC of 0.899 (95% CI, 0.849-0.949), outperforming the gene-based model (AUROC 0.670 [95% CI, 0.612-0.729]). A subsequent 24-protein classifier, developed via targeted mass spectrometry and validated in three independent sets, showed high performance in retrospective cohorts (AUROC 0.871 [95% CI, 0.833-0.910] and 0.853 [95% CI, 0.772-0.934]) and prospective biopsies (AUROC 0.781 [95% CI, 0.563-1.000]). It exhibited a 95.7% negative predictive value for ruling out malignancy. This study presents a promising protein-based approach for the differential diagnosis of FTA and FTC, potentially enhancing diagnostic accuracy and clinical decision-making.
期刊介绍:
EMBO Molecular Medicine is an open access journal in the field of experimental medicine, dedicated to science at the interface between clinical research and basic life sciences. In addition to human data, we welcome original studies performed in cells and/or animals provided they demonstrate human disease relevance.
To enhance and better specify our commitment to precision medicine, we have expanded the scope of EMM and call for contributions in the following fields:
Environmental health and medicine, in particular studies in the field of environmental medicine in its functional and mechanistic aspects (exposome studies, toxicology, biomarkers, modeling, and intervention).
Clinical studies and case reports - Human clinical studies providing decisive clues how to control a given disease (epidemiological, pathophysiological, therapeutic, and vaccine studies). Case reports supporting hypothesis-driven research on the disease.
Biomedical technologies - Studies that present innovative materials, tools, devices, and technologies with direct translational potential and applicability (imaging technologies, drug delivery systems, tissue engineering, and AI)